UB‐311, a novel UBITh ^® amyloid β peptide vaccine for mild Alzheimer's disease

Abstract

The UBITh^® platform can generate a high-precision molecular vaccine with high responder rate, strong on-target immunogenicity, and a potential of cognition improvement, which support UB-311 for active immunotherapy in early-to-mild AD patients currently enrolled in a phase-II trial (NCT02551809).